Actively Recruiting
24-Week Real-World Study of Atectura Inhalation Capsule for Asthma Treatment in Patients Aged 12 to 100 Years
Led by Novartis Pharmaceuticals · Updated on 2025-08-11
600
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This prospective, open-label, multicenter, single-arm, non-interventional, observational surveillance is designed to assess the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice. Three different doses of Atectura inhalation capsule will be prescribed via Breezhaler according to the approved label information in Korea. No additional diagnostic or monitoring procedures will be conducted specifically for this study.
CONDITIONS
Brief Title
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
